Marketing Communication CURE VanEck Genomics and Healthcare Innovators UCITS ETF Fund Details Fund Description 28 February 2025 Base CurrencyUSD The VanEck Genomics and Healthcare Innovators UCITS ETF (CURE) is a UCITS-compliant Inception Date 02 September 2022exchange-traded fund that invests in a portfolio of equity securities with the aim of providing Domicile Irelandinvestment returns that closely track the performance of the MVIS®Global Future Healthcare ESG Index. Net Assets USD 5.1M The MVIS® Global Future Healthcare ESG Index is a global index that tracks the performance of Shares Outstanding 260,000 companies that are involved in the genomic health care and electronic healthcare industries. Total Expense Ratio0.35% Performance History (%) Product Structure Physical (Full Replication) ETF Month End as of 28 Feb 2025 1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR INCEPTION UCITS Compliant Yes ETF -4.46 -4.27 2.50 -0.32 -- -- -- -1.49 Rebalance Frequency Semi-Annually MVFHCTR (Index) -4.45 -4.19 2.57 0.08 -5.52-- -- -1.18 Distribution Frequency None Income Treatment Reinvestment Past Performance as of 31 Dec 2024 Swiss Valor 1210310380% ISA Eligibility Yes SIPP AvailableYes -2% Countries of AT, CH, DE, DK, ES, FI, Registration FR, IE, IS, IT, LU, NL, NO, PL, PT, SE, UK -4% Index Information -6% Index ProviderMarketVector Indexes 2020 20212022 20232024 GmbH VanEck Genomics and Healthcare Innovators UCITS ETF Index Type Total Return NetBenchmark Index (MVIS Global Future Healthcare ESG Index) Currency USD 2020 2021 2022 2023 2024 Inception Date 06 Dec 2021 VanEck Genomics and Healthcare Innovators UCITS ETF -4.8-5.1 Rebalance Semi-Annually FrequencyBenchmark Index (MVIS Global Future Healthcare ESG Index)-4.6-4.8 Bloomberg Ticker MVFHCTRPast performance does not predict future returns. Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Performance data is displayed on a Net Reuters Ticker .MVFHCTR Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply. Returns may increase or decrease as a result of currency fluctuations. Investors must be aware Fund Datathat, due to market fluctuations and other factors, the performance of the ETFs may vary over time and should Number of Holdings 50consider a medium/long-term perspective when evaluating the performance of ETFs. Investing is subject to risks, including the possible loss of principal. Source: VanEck. Price/Earnings Ratio* 43.97 *Periods greater than one year are annualised. Price/Book Ratio*3.90 Weighted Avg. MCapUSD 30.7B * Last 12 Months Country Breakdown United States80.82% China 5.24% Germany4.69% Australia 3.59% Japan 2.04% Switzerland1.29% Other/Cash 2.33% Marketing Communication CURE VanEck Genomics and Healthcare Innovators UCITS ETF Top 10 Holdings28 February 2025 VERTEX PHARMACEUTICALS INC 8.63% REGENERON PHARMACEUTICALS INC 7.60% DEXCOM INC 7.52% VEEVA SYSTEMS INC 7.07% NATERA INC 5.88% ALNYLAM PHARMACEUTICALS INC5.10% INSULET CORP 4.70% BIONTECH SE4.40% PRO MEDICUS LTD3.59% ILLUMINA INC 3.47% SUBTOTAL - TOP 10 57.96% REMAINING HOLDINGS41.89% OTHER/CASH 0.15% TOTAL100.00% For a complete up-to-date listing of Fund holdings, please visit www.vaneck.com Trading Information TRADING EXCHANGE BLOOMBERGREUTERS IOPV EXCHANGE CURRENCY ISIN TICKER TICKER TICKER SEDOL SYMBOL LONDON STOCK EXCHANGEUSDIE000B9PQW54 CURE CURE LN CURE.LBQFP700 CUREUSIV LONDON STOCK EXCHANGEGBPIE000B9PQW54 CURG CURG LN CURG.LBQFP711 CUREUSIV DEUTSCHE BÖRSE EURIE000B9PQW54 CURE CURE GY CURE.DEBNG7JX1 CUREUSIV SIX SWISS EXCHANGE CHFIE000B9PQW54 CURE CURE SE CURE.SBNG7JZ3 CUREUSIV BORSA ITALIANA EURIE000B9PQW54 CURE CURE IMCURE.MIBNG7JY2 CUREUSIV Key Risks Liquidity Risk: This risk exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all. This is a factor to consider before investing in a Genomics ETF. Equity Market Risk: The prices of the securities in a Genomics ETF are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money. Industry or Sector Concentration Risk: The Fund’s assets may be concentrated in one or more particular sectors or industries. A Genomics ETF may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund’s assets were invested in a wider variety of sectors or industries. For more information on risks, please see the “Risk Factors” section of the relevant Fund’s prospectus, available on www.vaneck.com. IMPORTANT INFORMATION This is a marketing communication for professional investors only. Please refer to the UCITS prospectus and to the Key Investor Information Document (KIID) before making any final investment decisions. These documents are available in English and the KIDs in local languages and can be obtained free of charge at www.vaneck.com, from VanEck Asset Management B.V. (the “Management Company”) or, where applicable, from the relevant appointed facility agent for your country. This information originates from VanEck Securities UK Limited (FRN: 1002854), an Appointed Representative of Sturgeon Ventures LLP (FRN: 452811), who is authorised and regulated by the Financial Conduct Authority in the UK. The information is intended only to provide general and preliminary information to FCA regulated firms such as Independent Financial Advisors (IFAs) and Wealth Managers. Retail clients should not rely on any of the information provided and should seek assistance from an IFA for all investment guidance and advice. This material is only intended for general and preliminary information and shall not be construed as investment, legal or tax advice. VanEck Securities UK Limited and its associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision on the basis of this information. The views and opinions expressed are those of the author(s) but not necessarily those of VanEck. Opinions are current as of the publication date and are subject to change with market conditions. Information provided by third party sources is believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. VanEck Genomics and Healthcare Innovators UCITS ETF (the "ETF") is a sub-fund of VanEck UCITS ETFs plc, an open-ended variable capital umbrella investment company with limited liability between sub-funds. The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. The value of the ETF assets may fluctuate heavily as a result of the investment strategy. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets. MVIS® Global Future Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH (“MarketVector”), Solactive AG has no obligation to point out errors in the Index to third parties. VanEck’s ETF is not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the ETF. It is not possible to invest directly in an index. Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Performance data for the Irish domiciled ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Returns may increase or decrease as a result of currency fluctuations. Investors must be aware that, due to market fluctuations and other factors, the performance of the ETFs may vary over time and should consider a medium/long-term perspective when evaluating the performance of ETFs. Investing is subject to risk, including the possible loss of principal. Investors must buy and sell units of the UCITS on the secondary market via a an intermediary (e.g. a broker) and cannot usually be sold directly back to the UCITS. Brokerage fees may incur. The buying price may exceed, or the selling price may be lower than the current net asset value. The indicative net asset value (iNAV) of the UCITS is available on Bloomberg. The Management Company may terminate the marketing of the UCITS in one or more jurisdictions. The summary of the investor rights is available in English at: complaints-procedure.pdf (vaneck.com). For any unfamiliar technical terms, please refer to ETF Glossary | VanEck. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck. © VanEck Securities UK Limited